Therapeutic Handbook - GGC Prescribing

More documents

Recommendations

Info

Sepsis Source Unknown (not immunocompromised or neutropenic patients)InfectionsIndication Antibiotic therapy Notes / CommentsCommunity acquired orHealthcare associated sepsisor severe sepsis where thesource is unknownSuspected severestreptococcal infection(e.g. toxic shock, rapidlyprogressive soft tissueinfection)Benzylpenicillin IV 1.2 - 2.4 g6 hourlyandFlucloxacillin IV 2 g4 - 6 hourlyandGentamicin* IV (dosing infopage 262 )If true penicillin / beta-lactamallergy or MRSA suspected:Vancomycin IV (dosing infopage 266)andGentamicin* IV (dosing infopage 262)As for Community acquiredsepsis or severe sepsis wherethe source is unknown andadd in:Clindamycin* IV 600 mg6 hourly (up to 1200 mg6 hourly)E. coli, S. aureus andpneumococcus arecommonest community bloodculture isolates.Consider meningococcalinfection and S. pyogenes (e.g.pharyngitis, erythroderma orhypotension).Consider infective endocarditisin IVDU; line-related sepsis;recent dental extraction (seepage 216).Consider MRSA infection –sepsis arising > 48 hours postadmission, recent hospitaldischarge, post operativewound or line-related sepsis orsepsis in previous or currentMRSA carrier*Do not continue Gentamicinbeyond 3 - 4 days unlesson the advice of an infectionspecialist. If you are unsurewhether > 4 days is needed,contact an infection specialist.*Alert Antibiotic - complete AlertFormSeek advice from microbiology/ infectious diseases unit(Appendix 6 for contact details).Table continues on next pagePage 212
Sepsis Source Unknown (not immunocompromised or neutropenic) continued from previous pageIndication Antibiotic therapy Notes / CommentsProven S. aureus bacteraemiaSepsis syndrome secondaryto suspected urinary source(includes pyelonephritis withsepsis)Flucloxacillin IV 2 g4 - 6 hourlyIf true beta-lactam allergy orMRSA suspected then:Vancomycin IV (dosing info onpage 266)Duration 14 days IV or asadvised by infection specialistSee pages 220 (non-pregnantwomen), 221 (pregnantwomen) and 224 (in men)Replace intravascular device ifsource of infection.All patients require echo andinvestigation for possibleunderlying source.Discuss management(including duration of therapy)with microbiology / infectiousdiseases unit.Repeat blood cultures after 3 -4 days of effective therapy.InfectionsPage 213
Page 4:
ContentsEditorial GroupAcknowledgem
Page 8 and 9:
AppendicesAppendix 1 - Nicotine Rep
Page 10 and 11:
AcknowledgementsA huge number of pe
Page 12 and 13:
Summary of Major changes in Therape
Page 14 and 15:
On discharge• As the discharge pr
Page 16:
Other examples• Sevredol 10 mg ta
Page 19 and 20:
Antiplatelets and anticoagulants:In
Page 21 and 22:
non-Formulary medicines, a complete
Page 23 and 24:
Quick guide to using the handbookWh
Page 25 and 26:
Sections1. Resuscitation and Anaphy
Page 27 and 28:
Section 1Resuscitation and Anaphyla
Page 29 and 30:
Continued from previous page2. Adre
Page 31 and 32:
Peri-arrest ArrhythmiasGeneral advi
Page 33 and 34:
Broad QRS - continuedNarrow QRS - c
Page 35 and 36:
Guidelines on Blood TransfusionThis
Page 37 and 38:
Management of Major Haemorrhage(See
Page 39 and 40:
Hospital Specific Information on Ma
Page 41 and 42:
Table continued from previous pageG
Page 43 and 44:
Assessment / MonitoringAKI stage I
Page 45 and 46:
Section 2Drug Overdose and Toxicity
Page 47 and 48:
Treatment of Paracetamol OverdoseTh
Page 49:
Management of paracetamol overdose
Page 52 and 53:
Lithium toxicityNormal range 0.4 -
Page 54 and 55:
Management of DyspepsiaGastrointest
Page 57 and 58:
Table continued from previous pageR
Page 59 and 60:
Management of Gastroduodenal Ulcers
Page 61 and 62:
Management of Upper Gastrointestina
Page 63 and 64:
Post endoscopy continuedb. Arrange
Page 65 and 66:
General management and treatment op
Page 67 and 68:
- SAAG can differentiate ascites re
Page 69 and 70:
General management and drug therapy
Page 71 and 72:
Drug therapy• Unless contraindica
Page 73 and 74:
Consider:• Serum caeruloplasmin,
Page 75 and 76:
Section 4Cardiovascular SystemCardi
Page 77 and 78:
Table 1 - Indicators of patients at
Page 79 and 80:
Continued from previous pageIf the
Page 81 and 82:
Diagnosis and Treatment of VenousTh
Page 83 and 84:
Wells Clinical score should be util
Page 85 and 86:
IV Drug Misusers• Given their cha
Page 87 and 88:
Drug therapy / treatment options co
Page 89 and 90:
RivaroxabanRivaroxaban is an oral d
Page 91 and 92:
Diagnosis of VTE in pregnancy• If
Page 93 and 94:
Referral of Patients to Anticoagula
Page 95 and 96:
Reversal of Anticoagulant TherapyIn
Page 97 and 98:
Page 99 and 100:
Elective admissions - Risk Stratifi
Page 101:
Elective admissions - restarting an
Page 104 and 105:
Suspected Acute Coronary Syndrome (
Page 106 and 107:
If patient is for PPCI go to Box 1.
Page 108 and 109:
Drugs for acute coronary syndrome /
Page 110 and 111:
Secondary Prevention of Coronary He
Page 112 and 113:
Cardiovascular SystemTroponin posit
Page 114 and 115:
Atherosclerotic arterial disease is
Page 116 and 117:
Algorithm for Cardioversion of AFSt
Page 118 and 119:
Cardiovascular SystemVentricular ra
Page 120 and 121:
Prevention of stroke / thromboembol
Page 122 and 123:
Drugs for atrial fibrillation conti
Page 124 and 125:
CPAP in cardiogenic pulmonary oedem
Page 126 and 127:
Management of HypertensionCardiovas
Page 128 and 129:
Page 130 and 131:
Cardiovascular SystemGeneral manage
Page 132 and 133:
Management of Acute Stroke 3Transie
Page 134 and 135:
Secondary prevention of stroke and
Page 136 and 137:
Cardiovascular SystemPage 126
Page 138 and 139:
Guidelines for Blood Gas AnalysisRe
Page 140 and 141:
Respiratory SystemNext consider aci
Page 142 and 143:
Management of Acute Severe Asthmain
Page 144 and 145:
Management of Acute Severe Asthma i
Page 146 and 147:
Management of Chronic ObstructivePu
Page 148 and 149:
Acute Exacerbation of Chronic Obstr
Page 150 and 151:
Treatment options continued• If p
Page 153 and 154:
Step 4 - Initiation of NIVAIM = To
Page 155 and 156:
Investigation of Unilateral Pleural
Page 157 and 158:
Investigation of unilateral pleural
Page 159 and 160:
General management• Oxygen as app
Page 161 and 162:
Management of PneumothoraxIntroduct
Page 163 and 164:
Management of StridorIntroductionSt
Page 165 and 166:
Initial Management of Superior Vena
Page 167 and 168:
Section 6Central Nervous SystemCent
Page 169 and 170:
Analgesics for acute painSTEP 3STEP
Page 172 and 173: Analgesics for acute pain - prescri
Page 174 and 175: Management of Postoperative Nausea
Page 177 and 178: Management of Acutely Disturbed Pat
Page 179 and 180: Pharmacological Management - Patien
Page 181 and 182: Guidance on Night SedationPatients
Page 183 and 184: Management of Alcohol Withdrawal Sy
Page 185 and 186: Continued from previous pageUnable
Page 187 and 188: Continued from previous pageImporta
Page 189 and 190: Flow diagram for use with Hospital
Page 191 and 192: Continued from previous pageMethado
Page 193 and 194: Management of Suspected Subarachnoi
Page 195 and 196: Sampling requirements for the Bioch
Page 197 and 198: Referral to Neurosurgical Unit cont
Page 199 and 200: Management of Status EpilepticusInt
Page 201 and 202: OtherInitiating Long-term Anti-epil
Page 203 and 204: Continued from previous page2. 'Top
Page 205 and 206: Decision making algorithm for the a
Page 207 and 208: Drug therapy / treatment optionsNil
Page 209 and 210: Section 7InfectionsInfectionsPage 1
Page 211 and 212: • In patients with sepsis -- Star
Page 213 and 214: Gentamicin and Vancomycin: Reducing
Page 215 and 216: IV-Oral Antibiotic Switch Therapy (
Page 217 and 218: Alert Antibiotic Policy(The full ve
Page 219 and 220: Table 1 - Alert Antibiotics continu
Page 221: Infection Management GuidelinesSeve
Page 225 and 226: Table continued form previous pageI
Page 227 and 228: Table continued from previous pageE
Page 229 and 230: UTI in non-pregnant women Antibioti
Page 231 and 232: UTI in pregnant women Antibiotic Th
Page 233 and 234: Table continued from previous page
Page 235 and 236: Catheter-related UTI Antibiotic The
Page 237 and 238: Table continued from previous pageU
Page 239 and 240: Table continued from previous pageU
Page 241 and 242: Pneumonia(Also see page 148 for man
Page 243 and 244: Table continued from previous pageC
Page 245: Pneumonia (continued from previous
Page 248 and 249: InfectionsTable continued from prev
Page 250 and 251: Treatment of Clostridium difficile
Page 252 and 253: InfectionsSkin and soft tissue infe
Page 254 and 255: InfectionsSkin and soft tissue infe
Page 256 and 257: Central nervous system infectionsBa
Page 258 and 259: Meningitis Contacts• All suspecte
Page 260 and 261: Viral infectionsViral Encephalitis
Page 262 and 263: Guideline updated 11/10/13Genito-ur
Page 264 and 265: Genito-urinary infections (continue
Page 266 and 267: Patients with absent or non-functio
Page 268 and 269: MRSA Eradication Policy• In newly
Page 270 and 271: InfectionsDosage regimens for antib
Page 272 and 273:
Gentamicin dosing guidelines (For p
Page 274 and 275:
Step 2 continued from previous page
Page 276 and 277:
Vancomycin dosing guidelines (For p
Page 278 and 279:
Continued from previous page - If t
Page 280 and 281:
B. Vancomycin continuous infusionSt
Page 282 and 283:
Vancomycin - continuous infusion re
Page 284 and 285:
InfectionsPage 274
Page 286 and 287:
Management of Diabetic Ketoacidosis
Page 288 and 289:
Endocrine System5. Signs of cerebra
Page 290 and 291:
Assessment / monitoring• Glucose
Page 292 and 293:
Important points1. This regimen is
Page 294 and 295:
Diabetes therapy continued• Retro
Page 296 and 297:
Insulin Sliding Scale (Not for use
Page 298 and 299:
Management of HypoglycaemiaIntroduc
Page 300 and 301:
Endocrine SystemContinued from prev
Page 302 and 303:
Oral antidiabetic drugs continued3.
Page 304 and 305:
Other InformationGeneral advice on
Page 306:
Guideline updated 18/09/13Managemen
Page 309 and 310:
Page 311 and 312:
Management of hypomagnesaemia in ad
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Management of Hyponatraemia• Earl
Page 319 and 320:
Section 10Musculoskeletal and Joint
Page 321 and 322:
Treatment optionsManagement of acut
Page 323 and 324:
Treatment options continuedNSAIDs a
Page 325 and 326:
Section 11Palliative CarePalliative
Page 327 and 328:
Analgesic Step LadderStep 1: Mild P
Page 329 and 330:
Opioid Conversion ChartThis is advi
Page 331 and 332:
Palliative Care - SymptomsSee BNF,
Page 333 and 334:
Table continued from previous pageP
Page 335 and 336:
Management of symptoms present in l
Page 337 and 338:
Section 12Oncological EmergenciesOn
Page 339 and 340:
Malignant Spinal Cord Compression (
Page 341 and 342:
Raised intracranial pressure in can
Page 343 and 344:
Treatment /drug therapy continued5.
Page 345 and 346:
N.B.• Laboratory TLS = > 2 labora
Page 347 and 348:
• Avoid serum CA125 testing as it
Page 349 and 350:
AppendicesAppendicesPage 339
Page 351 and 352:
Appendix 2Preparation of Intravenou
Page 353 and 354:
Glyceryl Trinitrate (GTN) infusionG
Page 355 and 356:
Table 2 - Other drugsDrug Time to s
Page 357 and 358:
Appendix 5Normal ImmunoglobulinsNor
Page 359 and 360:
Drug MisuseHospital Liaison Addicti
Page 361 and 362:
Outpatient Parenteral Antibiotic Th
Page 363 and 364:
IndexPage 353
Page 365 and 366:
AnticoagulantsIn treatment of VTE/P
Page 367 and 368:
CiprofloxacinAlert Antibiotic Polic
Page 369 and 370:
EEmergency sedationGeneral principl
Page 371 and 372:
Hyoscine butylbromideIn palliative
Page 373 and 374:
Mesalazine, oralIn inflammatory bow
Page 375 and 376:
PhenytoinDosing and monitoring guid
Page 377 and 378:
TeicoplaninDosing and monitoring...
Page 379 and 380:
Notes
Page 381 and 382:
Notes
Page 384:
© NHS Greater Glasgow and ClydeAug
show all

Therapeutic Handbook - GGC Prescribing

Create successful ePaper yourself

Delete template?

Save as template?